Adjuvant activities in production of reaginic antibody by bacterial cell wall peptidoglycan or synthetic N-acetylmuramyl dipeptides in mice. 1979

H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata

This paper is concerned with the adjuvant activity in stimulatory immunoglobulin E production against ovalbumin (OA) by bacterial cell walls, cell wall peptidoglycan (PG), and their PG fragments and synthetic N-acetylmuramyl (MurNAc) dipeptides in A/J mice. A PG isolated from Streptococcus pyogenes, PG subunit polymer and dimer obtained from Staphylococcus epidermidis, and water-soluble fragments of cell walls or PG prepared from Nocardia corynebacteriodes and Streptomyces gardneri were found to enhance both the primary and secondary responses of anti-OA immunoglobulin E antibody production. It was suggested that the PG portion, either intact or highly degraded, was capable of enhancing the immunoglobulin E antibody production, and there was no need for the non-PG moiety or intactness of PG structure for the adjuvant activity. This finding was confirmed and extended by the use of synthetic MurNAc dipeptides. Among eight MurNAc dipeptides tested, MurNAc-l-Ala-d-isoGln, MurNAc-l-Ala-d-Gln, MurNAc-l-Ala-d-Glu, and MurNAc-l-Ser-d-isoGln were found active as an adjuvant in the stimulation of the primary and secondary reaginic anti-OA antibody production in a similar way to the cell wall PG and their fragments. None of the synthetic MurNAc-l-Ala-l-isoGln, MurNAc-l-Ala-l-Gln, MurNAc-l-Ala-l-Glu, and MurNAc-l-Ala-d-isoAsn, on the other hand, stimulated the anti-OA immunoglobulin E antibody production in either primary or secondary response, indicating the importance for the adjuvancy in immunoglobulin E production of the configuration of the glutamic acid residues adjacent to the l-Ala (or l-Ser) in muramyl dipeptides.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D008297 Male Males
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D010457 Peptidoglycan A structural polymer of the bacterial cell envelope consisting of sugars and amino acids which is responsible for both shape determination and cellular integrity under osmotic stress in virtually all bacteria. Murein,Pseudomurein
D002473 Cell Wall The outermost layer of a cell in most PLANTS; BACTERIA; FUNGI; and ALGAE. The cell wall is usually a rigid structure that lies external to the CELL MEMBRANE, and provides a protective barrier against physical or chemical agents. Cell Walls,Wall, Cell,Walls, Cell
D005260 Female Females
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
January 1982, Journal of medicinal chemistry,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
June 1981, Analytical biochemistry,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
January 1977, Infection and immunity,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
April 1981, The Journal of experimental medicine,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
November 1979, Infection and immunity,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
February 1976, Japanese journal of microbiology,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
November 1982, The Journal of pharmacy and pharmacology,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
January 1981, Infection and immunity,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
March 1994, Journal of pharmaceutical and biomedical analysis,
H Ohkuni, and Y Norose, and M Ohta, and M Hayama, and Y Kimura, and M Tsujimoto, and S Kotani, and T Shiba, and S Kusumoto, and K Yokogawa, and S Kawata
December 1954, Experientia,
Copied contents to your clipboard!